Keros Therapeutics, Inc. KROS

KROS Company Overview

Keros Therapeutics, Inc. is a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapeutics that modulate signaling pathways within the transforming growth factor‑beta (TGF‑β) superfamily. The company operates within the biopharmaceutical and life sciences industries, with a primary emphasis on developing biologic therapies for hematologic disorders and cardiopulmonary diseases with significant unmet medical need. Its core approach centers on engineered ligand trap proteins designed to selectively regulate disease‑relevant signaling.

The company’s principal revenue drivers are its clinical development programs, as it does not generate product sales and relies primarily on equity financing. Keros targets patient populations with conditions such as anemia associated with myelodysplastic syndromes and myelofibrosis, as well as pulmonary arterial hypertension. Its strategic positioning is based on proprietary protein engineering capabilities and deep specialization in TGF‑β biology. Keros was founded in 2015 and emerged from scientific research and company‑building efforts supported by venture capital, evolving into a publicly traded company following its initial public offering in 2020.